ZS Ph2/3 Dose-response Study in Japan

A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia

To assess efficacy of 5 g three times daily (TID) and 10 g TID ZS versus placebo in Japanese patients with hyperkalemia (serum potassium [S-K] ≥ 5.1 mmol/L and ≤ 6.5 mmol/L).

Study Overview

• Status: Completed
• Conditions: Hyperkalemia
• Intervention / Treatment: Drug: Sodium Zirconium Cyclosilicate (ZS) 5g; Drug: Sodium Zirconium Cyclosilicate (ZS) 10g; Drug: Placebo

Detailed Description

Patients not receiving any therapy for hyperkalemia and with 2 consecutive i-STAT potassium values of ≥ 5.1 mmol/L and ≤ 6.5 mmol/L will be enrolled and randomized 1:1:1 to receive ZS 5 g, ZS 10 g, or placebo TID for 48 hours.

Throughout the study most potassium values will be measured at fasting before taking study drug. Nothing should be taken by mouth except water, coffee or tea, with or without milk and/or sugar, and essential medications, prior to the blood collection for a minimum of 8 hours. Potassium level should be determined by both i-STAT and the Central Laboratory on all occasions. Treatment decisions (eg, stopping rules) will be made based on i-STAT potassium values, as these provide clinical sites with a real-time measurement. Statistical analyses on the study data will in principle be based on S-K values as measured by the central laboratory.

Safety and tolerability will be assessed on an ongoing basis. Standard study assessments including blood potassium, clinical chemistry (including calcium, magnesium, sodium, phosphate, creatinine, bicarbonate, and blood urea nitrogen [BUN]) and hematology parameters, urinalysis, vital signs, physical examinations, and electrocardiograms (ECGs) will be assessed during the study at the time points specified in the assessments schedule. All women of childbearing potential will have a urine pregnancy test prior to enrollment and at their End of Study (EOS) visit.

Stopping rules will be implemented to ensure subjects discontinue the study treatment and receive alternative therapy in case of significant hyperkalemia, hypokalemia, or significant cardiac arrhythmias.

• Study Type: Interventional
• Enrollment (Actual): 103
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Japan
  • Chiba-shi, Japan, 260-8712
    • Research Site
  • Chiba-shi, Japan, 263-0043
    • Research Site
  • Hanyu-shi, Japan, 348-8505
    • Research Site
  • Higashiibaraki-gun, Japan, 311-3193
    • Research Site
  • Hitachinaka-shi, Japan, 312-0057
    • Research Site
  • Ina-shi, Japan, 396-8555
    • Research Site
  • Kagoshima-shi, Japan, 892-8580
    • Research Site
  • Kahoku-gun, Japan, 920-0293
    • Research Site
  • Kamakura-shi, Japan, 247-8533
    • Research Site
  • Kanazawa-shi, Japan, 920-8650
    • Research Site
  • Kasugai-shi, Japan, 486-8510
    • Research Site
  • Kawachinagano-shi, Japan, 586-8521
    • Research Site
  • Kawasaki-shi, Japan, 216-8511
    • Research Site
  • Kitakyushu-shi, Japan, 802-0001
    • Research Site
  • Koga-shi, Japan, 306-0041
    • Research Site
  • Kusatsu-shi, Japan, 525-8585
    • Research Site
  • Matsudo-shi, Japan, 271-0077
    • Research Site
  • Matsuyama-shi, Japan, 791-8026
    • Research Site
  • Nagoya-shi, Japan, 457-8511
    • Research Site
  • Naka-shi, Japan, 311-0113
    • Research Site
  • Omura-shi, Japan, 856-8562
    • Research Site
  • Shimajiri-gun, Japan, 901-0493
    • Research Site
  • Shizuoka-shi, Japan, 421-0117
    • Research Site
  • Yao-shi, Japan, 581-0011
    • Research Site
  • Yotsukaido-shi, Japan, 284-0027
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures.
• Patients aged ≥18. For patients aged <20 years, a written informed consent should be obtained from the patient and his or her legally acceptable representative.
• Two consecutive i-STAT potassium values, measured 60 (± 10) minutes apart, both values should be ≥ 5.1 mmol/L and ≤ 6.5 mmol/L and measured within 1 day before the first dose of study drug on Study Day 1.
• Ability to have repeated blood draws or effective venous catheterization.
• Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of ZS/matching placebo to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used.

Exclusion Criteria:

• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)

• Cause or symptoms of pseudohyperkalemia, such as

  1. hemolyzed blood specimen due to excessive fist clenching to make veins prominent
  2. hemolyzed blood specimen due to difficult or traumatic venepuncture
  3. history of severe leukocytosis or thrombocytosis
• Patients treated with lactulose, rifaximin, or other non-absorbed antibiotics for hyperammonemia within 7 days prior to first dose of study drug on Study Day 1
• Patients treated with resins (such as sevelamer hydrochloride, sodium polystyrene sulfonate [SPS; e.g. Kayexalate®] or calcium polystyrene sulfonate [CPS]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug
• Patients with a life expectancy of less than 3 months
• Patients who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the patients' tasks associated with the protocol
• Female patients who are pregnant, lactating, or planning to become pregnant
• Patients who have an active or history of diabetic ketoacidosis
• Presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardizes the quality of the data to be generated
• Known hypersensitivity or previous anaphylaxis to ZS or to components thereof
• Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry
• Patients with cardiac arrhythmias that require immediate treatment
• Patients on dialysis

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sodium Zirconium Cyclosilicate (ZS) 5g; Suspension administered 5g orally three times daily for 48 hours.	Drug: Sodium Zirconium Cyclosilicate (ZS) 5g; Suspension administered 5g orally three times daily for 48 hours.
Experimental: Sodium Zirconium Cyclosilicate (ZS) 10g; Suspension administered 10g orally three times daily for 48 hours.	Drug: Sodium Zirconium Cyclosilicate (ZS) 10g; Suspension administered 10g orally three times daily for 48 hours.
Placebo Comparator: Placebo; Placebo suspension administered orally placebo three times daily for 48 hours.	Drug: Placebo; Placebo suspension administered orally placebo three times daily for 48 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment	Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or <4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.	From 0 to 48 hours.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Patients Who Achieved Normokalaemia at 48 Hours	The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 48 hours after start of dosing was determined. Patients with missing S-K values at 48 hours were regarded as not normokalaemic.	At 48 hours.
Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment	Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or <4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 24 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.	From 0 to 24 hours.
Percentage of Patients Who Achieved Normokalaemia at 24 Hours	The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 24 hours after start of dosing was determined. Patients with missing S-K values at 24 hours were regarded as not normokalaemic.	At 24 hours.
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point	The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at each each scheduled potassium assessment time point after the start of dosing was determined. Patients with missing S-K values were regarded as not normokalaemic.	From baseline to end of study (9 days).
Mean Change From Baseline in S-K Values at All Measured Time Intervals	Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or <4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean change from baseline is displayed.	From baseline to end of study (9 days).
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals	Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or <4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean percent change from baseline is displayed.	From baseline to end of study (9 days).
Time to Normalisation in S-K Values	The distribution of time to normalisation of S-K values (defined as S-K values between 3.5 mmol/L and 5.0 mmol/L, inclusive) was measured. A patient who reached at least one S-K within normal range was counted as an event regardless of S-K value after that time point. Patients who did not achieve normokalaemia within 48 hours were censored.	From 0 to 48 hours.
Time to a Decrease in S-K Levels of 0.5 mmol/L	The median time (hours) for S-K values to decrease by 0.5 mmol/L was measured.	From 0 to 48 hours.

Collaborators and Investigators

• Sponsor: AstraZeneca

Publications and helpful links

General Publications

• Kashihara N, Nishio T, Osonoi T, Saka Y, Imasawa T, Ohtake T, Mizuno H, Shibagaki Y, Kim H, Yajima T, Sarai N. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study. Clin Exp Nephrol. 2020 Dec;24(12):1144-1153. doi: 10.1007/s10157-020-01937-1. Epub 2020 Aug 10.

Study record dates

Study Major Dates

• Study Start (Actual): June 14, 2017
• Primary Completion (Actual): February 23, 2018
• Study Completion (Actual): February 23, 2018

Study Registration Dates

• First Submitted: April 5, 2017
• First Submitted That Met QC Criteria: April 20, 2017
• First Posted (Actual): April 25, 2017

Study Record Updates

• Last Update Posted (Actual): May 20, 2019
• Last Update Submitted That Met QC Criteria: February 20, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Water-Electrolyte Imbalance; Hyperkalemia
• Other Study ID Numbers: D9482C00002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No